On 03.31.2017, FIT Group JSC (code FIT) announced the successful purchase of more than 1 million shares of Cuu Long Pharmaceutical JSC.
With this plan, after completing the purchase, FIT will increase its ownership in DCL from 69.95% to 71.72%.
For 2017, DCL has set a plan to achieve net sales of 914 billion and profit after tax of 96 billion, respectively up 24% and 7% compared to 2016 during which DCL reached 738 billion in net sales and 90 billion in net profit after tax.
2016 is the 3rd consecutive year where DCL achieved business growth with profit after tax increasing by 50% during the period. DCL impressed not only on business results but also with the successful implementation of Euvipharm from Valeant, one of the most modern factories in Vietnam.
In coming future, with the support of FIT Group JSC, DCL expects to expand into new areas such oncology products with the creation of Benovas oncology JSC.
